Promore Pharma
9.11.2021 12:02:15 CET | ACCESS Newswire | Press release
STOCKHOLM, SE / ACCESSWIRE / November 9, 2021 / Promore Pharma (STO:PROMO)(FRA:8T0)
Stockholm, November 9, 2021 - Promore Pharma AB, a Swedish biopharmaceutical company that develops peptide-based drug candidates, announced today that the company has received approval from the Medical Products Agency and the Swedish Ethics Review Authority to begin a clinical phase II trial of ensereptide for skin scarring prevention.
The company announces today that a clinical trial permit has been obtained from the Medical Products Agency in Sweden and that the company's application for approval from the Ethical Review Authority has also been granted. PHSU05 is a Phase II pilot study with the aim of being able to evaluate ensereptide regarding (i) local tolerance, (ii) the application process of the experimental drug, and (iii) preliminary effect on scar prevention after experimentally induced wounds in healthy volunteers. Planned study start is Q1 2022 and results from the study are expected in the winter of 2022/2023.
"This is an important step in our long-term goal of developing a new product concept to prevent the occurrence of post-surgical and post-traumatic scars on the skin. These approvals are fully aligned with our operational plan in the ensereptide project ", says Jonas Ekblom, CEO of Promore Pharma.
Bolagets ensereptide-program fokuseras för närvarande på prevention av ärr i huden i samband med kirurgi eller trauma, men det finns även potential att utveckla produkten för andra medicinska applikationer som prevention av sammanväxning efter hand- och ryggradskirurgi.
The company's ensereptide program is currently focused on the prevention of scarring of the skin in connection with surgery or trauma, but there is also potential to develop the product for other medical applications such as prevention of adhesions after surgeries in the hand or spine.
Scars develop after virtually all types of damage to the skin. Although scars can often be considered trivial, a large proportion of them can be disfiguring and aesthetically pleasing, and they can also create itching, stiffness, sleep problems, anxiety, depression and negatively affect activities of daily life.
The world market for products for the treatment of scars, including laser treatment, scar revision and self-care products, amounts to USD 25 billion with an annual growth of about 10%, according to independent estimates. Today, there are no prescription drugs for wound prevention.
For additional information, please contact
Jonas Ekblom, CEO
Phone: [+46] 736 777 540
E-mail: jonas.ekblom@promorepharma.com
Erik Magnusson, CFO
Phone: [+46] 708 565 245
E-mail: erik.magnusson@promorepharma.com
Promore Pharmas Certified Adviser is Erik Penser Bank
Tel: [+46] 8-463 83 00
E-mail: certifiedadviser@penser.se
Promore Pharma in brief
Promore Pharma is a biopharmaceutical company specialized in the development of therapeutic peptides. The company's aim is to develop first-in-category pharmaceuticals for indications with high unmet medical needs, where very few efficacious prescription pharmaceuticals are available. Promore Pharma's two projects are undergoing clinical development and have a very strong safety profile since the products are based on endogeneous substances that are administered locally. The leading project, ensereptide (PXL01), that will be used for prevention of post-surgical scarring, is being prepared for a clinical phase II-trial if the peptide can prevent the formation of unesthetical scars on the skin. Ropocamptide (LL-37) has recently been evaluated in a clinical phase IIb study with positive results in patients with venous leg ulcers (VLUs). The product candidates can also be deployed for other indications, such as preventing unfavorable tissue attachments (adhesions) after different kinds of surgical procedures and treatment of diabetic foot ulcers. The company is listed on Nasdaq First North Growth Market.
This information is information that Promore Pharma is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2021-11-09 11:38 CET.
Attachments
Promore Pharma receives permits to start a phase II clinical trial regarding scar prevention
SOURCE: Promore Pharma
View source version on accesswire.com:
https://www.accesswire.com/671849/Promore-Pharma-Receives-Permits-to-Start-a-Phase-II-Clinical-Trial-Regarding-Scar-Prevention
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Merchant Payments Ecosystem Announces Winners of the MPE Awards 202627.3.2026 12:00:00 CET | Press release
Industry leaders, innovators and emerging companies were recognized in Berlin for excellence across the merchant payments ecosystem. BERLIN, GERMANY / ACCESS Newswire / March 27, 2026 / Merchant Payments Ecosystem (MPE) today announced the winners of the MPE Awards 2026, recognizing the companies and individuals driving innovation, leadership and measurable impact across the merchant payments value chain. Presented during the MPE Awards Gala in Berlin on March 18, the annual awards celebrated excellence across payment acceptance, orchestration, embedded finance, open banking, fraud and compliance, identity, settlement, merchant-led innovation and more. With 177 entries submitted this year, the MPE Awards 2026 highlighted the scale, competitiveness and diversity of innovation shaping the future of merchant payments. The central theme of this year's awards was "Transformation through Trust & Resilience." "The MPE Awards 2026 winners demonstrate that the future of merchant payments will b
RE Royalties Announces Strategic Review to Evaluate Path for Long-Term Value Creation27.3.2026 11:00:00 CET | Press release
All amounts in CAD dollars unless otherwise stated. VANCOUVER, BC / ACCESS Newswire / March 27, 2026 / RE Royalties Ltd. (TSXV:RE)(OTCQX:RROYF)(FSE:Y2V) ("RE Royalties" or the "Company") today announced that its Board of Directors (the "Board") has initiated a formal review of strategic alternatives (the "Strategic Review") to identify opportunities to maximize value for shareholders. As part of this process, the Board will evaluate a broad range of potential alternatives, including, but not limited to, a sale of the Company, strategic or co-investment partnerships, or capital structure optimizations through equity or debt financings. The Strategic Review represents a natural evolution for RE Royalties as the Company enters its 11th year of operations and seeks to position itself for future growth. The Strategic Review follows a formal recommendation from management. A Special Committee of the Board ("Special Committee") has been established to lead the process and oversee the evaluati
Clean Air Metals Receives Provincial Funding and Provides Update on the Thunder Bay North Project26.3.2026 22:00:00 CET | Press release
THUNDER BAY, ON / ACCESS Newswire / March 26, 2026 / Clean Air Metals Inc. ("Clean Air Metals" or the "Company") (TSXV:AIR)(FRA:CKU)(OTCQB:CLRMF) is pleased to provide an update on its 100%-owned Thunder Bay North ("TBN") Critical Minerals Project in Northwestern Ontario. Company Financing update The Company has been approved for up to $200,000 in government funding as part of the Ontario Junior Exploration Program (OJEP) that will be used to advance work in the 2.5 km long Escape down-plunge target, where it recently intersected 53m of resource-grade mineralization in the initial exploration hole (Figure 1 and October 20, 2025 release). "Ontario is leading the charge to secure the minerals that will power our economy and strengthen our sovereignty," said Stephen Lecce, Minister of Energy and Mines. "Through OJEP, we're backing companies like Clean Air Metals Inc. to advance promising projects here at home-unlocking resources, creating jobs, and building a more self-reliant and secure
LHH 2026 C-Suite Research: Executive Turnover Falls Sharply as AI Accountability and Decision-Making Gaps Define Leadership Agenda26.3.2026 17:05:00 CET | Press release
High-turnover leadership teams drop from 43% to 19% year-over-year; AI identified as the #1 executive skill gap. NEW YORK CITY, NY / ACCESS Newswire / March 26, 2026 / LHH, the integrated professional talent solutions provider and global business unit of the Adecco Group, released its 2026 View from the C-Suite report, examining executive priorities, leadership skill gaps, and organizational performance internationally. The report highlights a notable shift in the executive landscape: while turnover is falling, the expectations and pressures on leaders are intensifying across technology, decision-making, and talent strategy. Brief The annual View from the C-Suite report finds that executive turnover is declining significantly. Leaders are navigating high external pressures, including economic uncertainty, market volatility, inflation, rising costs, and heightened data security risks. Internal priorities are increasingly focused on talent retention, team effectiveness, and employee well
Multi-Billion-Dollar Sports Brand U.S. Polo Assn. Launches Global Polo Shirt Campaign: An Icon Born from the Game26.3.2026 12:00:00 CET | Press release
WEST PALM BEACH, FLA. / ACCESS Newswire / March 26, 2026 / U.S. Polo Assn., the official sports brand of the United States Polo Association (USPA) founded in 1890, today announced the launch of its Global Polo Shirt Campaign, An Icon Born from the Game. The global campaign is a powerful tribute to the iconic polo shirt's authentic sports origins and its evolution into one of the world's most enduring style essentials.1. U.S. Polo Assn. Global Brand Ambassador, 6-goal American professional polo player Nico Escobar takes in the game atop his equine partner, wearing polo whites and a classic navy U.S. Polo Assn. polo shirt, An Icon Born from the Game 2. U.S. Polo Assn. models in polo shirts at the Spring-Summer 2026 Global Collection Photoshoot in Charleston, South Carolina 3. ‘The Polo Shirt: An Icon Born From the Game' campaign imagery featuring U.S. Polo Assn. models The polo shirt's beginning was born on the polo fields, shaped by motion, competition, and the spirit of the game for wh
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom